A Phase 1/2 Study of Safety, Efficacy, and Pharmacodynamics of a 60-Minute Infusion of Carfilzomib for Patients With Progressive Multiple Myeloma
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone
- Indications Multiple myeloma
- Focus Adverse reactions
- Sponsors Biomira USA
- 01 Mar 2018 Planned End Date changed from 1 Mar 2018 to 1 Dec 2018.
- 01 Mar 2018 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 27 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Mar 2018.